



**smith & hopen, p.a.**

Intellectual Property Law Patents Trademarks Copyrights

January 5, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Applicant: Kapil N. Bhalla et al.**

**Serial No.: 10/605,283**

**Filing Date: 09/19/2003**

**For: Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate**

**Our Reference No.: 1372.76.PRC**

**Examiner: Unassigned**

**Art Unit: 1756**

**Confirmation No.: 2282**

Dear Sir:

Enclosed please find the following:

1. Information Disclosure Statement By Applicant- 1 page;
2. Copies of three (3) Non-Patent Literature Documents; and
3. Self-addressed, postage prepaid post card to serve as a receipt for items 1 and 2.

Very respectfully,

**SMITH & HOPEN**

By: Anton J. Hopen  
*anton.hopen@baypatents.com*

AJH/dp  
enclosure

**CERTIFICATE OF MAILING**  
(37 C.F.R. 1.8)

I HEREBY CERTIFY that this correspondence is being mailed with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 5, 2004.

Date: January 5, 2004

  
Deborah Preza

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

### Complete if Known

|                        |                        |
|------------------------|------------------------|
| Application Number     | 10/605,283             |
| Filing Date            | 09/19/2003             |
| First Named Inventor   | Kapil N. Bhalla et al. |
| Group Art Unit         | 3679                   |
| Examiner Name          | Unassigned             |
| Attorney Docket Number | 1372.76.PRC            |

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner<br>Initials <sup>1</sup> | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|-----------------------------------|--------------------------|---|----------------|
|                                   | 1                        | NIMMANAPALLI, RAMEDEVI ET AL. Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal ... Cancer Research 63, 5126-5135, August 15, 2003.  |                |
|                                   | 2                        | NIMMANAPALLI, RAMADEVI ET AL. Cotreatment with the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid... Neoplasia, Blood, 15 April 2003, Volume 101, Number 8.  |                |
|                                   |                          |   |                |
|                                   |                          |   |                |
|                                   |                          |   |                |
|                                   |                          |   |                |
|                                   |                          |   |                |
|                                   |                          |   |                |
|                                   |                          |   |                |
|                                   |                          |   |                |
|                                   |                          |   |                |
|                                   |                          |   |                |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.